Diabetes Trials Unit
The Diabetes Trials Unit (DTU) is a UKCRC accredited clinical trials unit specialising in performing local, national and multinational clinical trials related to treating and managing diabetes and other cardiometabolic and related conditions. We work collaboratively with researchers and organisations to support trials and other studies.
Director
-
Amanda Adler
Professor of Diabetic Medicine and Health Policy
What's new
Early blood glucose control for people with type 2 diabetes is crucial for reducing complications and prolonging life
18 May 2024
Research led by scientists from the Universities of Oxford and Edinburgh has found that early good blood glucose control can minimise the lifetime risk of diabetes-related complications, including heart attacks, kidney failure and vision loss.
The LEGEND-D Trial – which aims to prevent low blood sugar levels in type 1 diabetes – is open to recruitment
16 April 2024
The first participant has completed initial study activities and is now randomised to one of the trial’s arms.
DTU to run clinical trial for Dementias Platform UK in nationwide bid to revolutionise dementia diagnosis using blood tests
4 April 2024
Dementias Platform UK has been awarded over £4 million to carry out countrywide trials to identify accurate and quick blood tests that can diagnose dementia, in a bid to improve management and patient and carer wellbeing. RDM's Diabetes Trials Unit will run the clinical trial component of the challenge.
UK’s first registry to be set up for those at risk of type 1 diabetes
11 March 2024
Researchers from the Oxford BRC and other collaborating organisations have received funding to set up a UK registry for children and adults who are at risk of type 1 diabetes and have tested positive for diabetes autoantibodies.
Professor Rury Holman wins 2024 Banting Medal for Scientific Achievement
6 March 2024
The American Diabetes Association (ADA) has announced this year's National Scientific and Health Care Achievement Award recipients.
Latest publications
-
Estimating Risk Factor Time Paths Among People with Type 2 Diabetes and QALY Gains from Risk Factor Management
Journal article
Gao N. et al, (2024), PharmacoEconomics
-
Protocol for a double-blind placebo-controlled randomised controlled trial assessing the impact of oral semaglutide in amyloid positivity (ISAP) in community dwelling UK adults.
Journal article
Koychev I. et al, (2024), BMJ Open, 14
-
Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 years (UKPDS 91).
Journal article
Adler AI. et al, (2024), Lancet
-
Comparative effectiveness of second line oral antidiabetic treatments among people with type 2 diabetes mellitus: emulation of a target trial using routinely collected health data.
Journal article
Bidulka P. et al, (2024), BMJ, 385
-
Overcoming challenges in the economic evaluation of interventions to optimise antibiotic use
Journal article
ROOPE L. et al, (2024), Communications Medicine